Home | Safety evaluation of Recombinant Human Erythropoietin ior EPOCIM in the treatment of patient with cerebral infarction acute. Study Stage I.
Published clinical_trials Safety evaluation of Recombinant Human Erythropoietin ior EPOCIM in the treatment of patient with cerebral infarction acute. Study Stage I. has 2 revisions.
RevisionStatus
Saved 01/06/2017 - 2:11pm by CIMAB
in draft/pending publication
Saved 01/06/2017 - 2:11pm by CIMAB
current revision (published)
Equipo de Trabajo del RPCEC | CENCEC - MINSAP
rpcec@cencec.sld.cu
Calle 5ta A Edificio CECMED-CENCEC 2do piso e/ 60 y 62 Miramar, Playa.CP 11300. La Habana, Cuba
Telef: (537) 216-4126 | (537) 216-4212 | (537) 216-4218.
Copyright © 2014-2022 All Rights Reserved.